Good evening :)
IND Swift Laboratories Ltd

IND Swift Laboratories Ltd

INDSWFTLAB Share Price

NSE
₹385.752.09% (-8.25)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹3,436 cr, stock is ranked 1,018

Stock is 4.29x as volatile as Nifty

INDSWFTLAB Stock Scorecard

Performance

High

The creamy layer - amongst the top performing stocks

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

With a market cap of ₹3,436 cr, stock is ranked 1,018

Stock is 4.29x as volatile as Nifty

INDSWFTLAB Performance & Key Metrics

INDSWFTLAB Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
59.952.48—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
45.785.740.50%

INDSWFTLAB Analyst Ratings & Forecast

—
Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

INDSWFTLAB Company Profile

Ind-Swift Laboratories Limited is a company focused on the development of active pharmaceutical ingredients (APIs).

Investor Presentation

View older View older 

Aug 17, 2026

PDF
View Older Presentations

INDSWFTLAB Similar Stocks (Peers)

Compare with peers Compare with peers 

INDSWFTLAB Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
37.64
37.64
1Y Return
7.43%
7.43%
Buy Reco %
93.33
93.33
PE Ratio
83.82
83.82
1Y Return
34.44%
34.44%
Buy Reco %
81.48
81.48
PE Ratio
22.68
22.68
1Y Return
14.51%
14.51%
Buy Reco %
55.56
55.56
PE Ratio
27.99
27.99
1Y Return
12.06%
12.06%
Buy Reco %
62.86
62.86
LAURUSLABS
PE Ratio
120.61
120.61
1Y Return
127.49%
127.49%
Buy Reco %
58.33
58.33
Compare with Peers

INDSWFTLAB Sentiment Analysis

INDSWFTLAB Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

INDSWFTLAB Stock Summary · August 2026

Management struck a confident tone after a sharp profitability rebound, with operating income up 21.16% year on year to ₹186.08 crore and EBITDA margin expanding to 17.91%, while PAT excluding exceptional items more than doubled to ₹24.68 crore. It said the improvement was driven by a richer mix, as export own-brands rose to 57.20% of sales from 48% a year ago, supporting both deeper regulated-market penetration and better margins. A key focus was the early commercialization of CDMO partnerships with Viatris, Manx and Arrotex, although the near-term ramp is slower than initially suggested: the new contribution was only about ₹5-6 crore in the quarter, with the Viatris molecules expected to add roughly ₹100-130 crore in year one and scale over a two-year horizon. The company also highlighted new product launches and the Samba facility upgrade, alongside planned use of its roughly ₹250 crore cash balance for capacity and compliance work. Management said 18% EBITDA margins are sustainable, expects margins to move above 20% after the second quarter, and reiterated its FY30 targets of at least ₹1,500 crore in revenue and about ₹200 crore-plus in net profit.

INDSWFTLAB Stock Growth Drivers
INDSWFTLAB Stock Growth Drivers
8
  • Strong Operating Momentum and Profitability Expansion

    The company delivered a strong start to FY27, with operating income rising 21.16% year on

  • Export-Led Mix Shift Toward Higher-Margin Own Brands

    The business continues to shift meaningfully toward exports and higher-margin own brands, with export own-brand

INDSWFTLAB Stock Challenges
INDSWFTLAB Stock Challenges
3
  • Weaker Domestic Revenue Mix

    The company’s sales mix has shifted further away from domestic businesses, which points to declining

  • Legacy Leverage and Restructuring Stress

    The business has a history of severe financial stress, including high leverage, weak debt-servicing capacity,

INDSWFTLAB Forecast

INDSWFTLAB Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

INDSWFTLAB

INDSWFTLAB

Income

Balance Sheet

Cash Flow

INDSWFTLAB Income Statement

INDSWFTLAB Income Statement

Loading...

Quartermar 2024jun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026jun 2026
Total Revenue986.8044.3124.96145.43358.57167.32170.50178.43172.01199.11
Operating & Other expensessubtract437.3642.9123.75136.17147.43149.13151.17152.53154.37158.26
Depreciation/Amortizationsubtract19.550.250.225.817.446.686.988.848.127.58
Interest & Other Itemssubtract2.960.170.4110.03-26.761.152.010.67-2.430.71
Taxes & Other Itemssubtract33.260.040.17-1.098.191.582.356.85-3.167.88
EPS83.550.160.07-0.8232.961.281.001.171.812.84

INDSWFTLAB Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2027FY 2027

Annual Report Pending

Investor Presentation

Aug 17PDF
FY 2026FY 2026

Annual report

PDF

Investor Presentation

Feb 4PDF
FY 2025FY 2025

Annual report

PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF

Investor Presentation

Nov 18PDF
Jul 31PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
 

INDSWFTLAB Stock Peers

INDSWFTLAB Past Performance & Peer Comparison

INDSWFTLAB Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
IND Swift Laboratories Ltd79.672.48—
Sun Pharmaceutical Industries Ltd37.645.150.89%
Torrent Pharmaceuticals Ltd83.8210.310.71%
Zydus Lifesciences Ltd22.683.860.09%

INDSWFTLAB Stock Price Comparison

Compare INDSWFTLAB with any stock or ETF
Compare INDSWFTLAB with any stock or ETF
INDSWFTLAB
Loading...

INDSWFTLAB Holdings

INDSWFTLAB Shareholdings

INDSWFTLAB Promoter Holdings Trend

INDSWFTLAB Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

INDSWFTLAB Institutional Holdings Trend

INDSWFTLAB Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

INDSWFTLAB Shareholding Pattern

INDSWFTLAB Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding42.93%0.00%0.15%10.90%46.01%

Feb 2026

Mar 2026

Jun 2026

Sep 2026

INDSWFTLAB Shareholding History

INDSWFTLAB Shareholding History

SepDec '25FebMarJunSep14.80%14.33%13.80%13.88%10.70%10.90%

INDSWFTLAB Insider Trades & Bulk Stock Deals

INDSWFTLAB Insider Trades & Bulk Stock Deals

Loading...

smallcases containing INDSWFTLAB stock

smallcases containing INDSWFTLAB stock

Looks like this stock is not in any smallcase yet.

INDSWFTLAB Events

INDSWFTLAB Events

INDSWFTLAB Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

INDSWFTLAB has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

INDSWFTLAB Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

INDSWFTLAB has not given any dividends in last 5 years

INDSWFTLAB Upcoming Dividends

INDSWFTLAB Upcoming Dividends

No upcoming dividends are available

INDSWFTLAB Past Dividends

INDSWFTLAB Past Dividends

Cash Dividend

Ex DateEx DateSep 20, 2011

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Sep 20, 2011

Cash Dividend

Ex DateEx DateSep 16, 2010

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Sep 16, 2010

INDSWFTLAB Stock News & Opinions

INDSWFTLAB Stock News & Opinions

Corporate
Corporate
Ind-Swift Laboratories restricts trading for insiders ahead of September 2026 results

Ind-Swift Laboratories Ltd. will close its trading window for promoters, members of the promoter group, directors, key managerial personnel, designated persons, connected persons/insiders and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, in compliance with securities regulations and the company’s code of fair disclosure.

6 days agoCapital Market - Live
Corporate
Corporate
Ind-Swift Laboratories allotted warrants valued at Rs 34.3 crore to Essix Biosciences

Ind-Swift Laboratories Limited announced that its Preferential Issue Committee approved the allotment of 70,00,000 fully convertible warrants at a price of Rs 196 per warrant, including a premium of Rs 186, to Essix Biosciences Limited, an entity belonging to the ‘Promoter & Promoter Group,’ for a total subscription price of Rs 34,30,00,000.

2 weeks agoCapital Market - Live
Corporate
Corporate
IND-SWIFT Laboratories appoints Amit Mathur as Additional Director for five years

IND-SWIFT LABORATORIES LTD. announced the appointment of Mr. Amit Mathur as an Additional Director, in the category of Non-Executive Independent Director, effective September 3, 2026, for a period of five years subject to member approval at the company’s 31st Annual General Meeting, scheduled for September 30, 2026. The company also announced the reconstitution of its Audit Committee, effective September 3, 2026, and appointed Care Ratings Limited as the Monitoring Agency for the utilization of proceeds from a preferential issue approved on August 5, 2026.

1 month agoCapital Market - Live
Spotlight
Spotlight
Ind-Swift Laboratories Ltd leads gainers in 'B' group

Shekhawati Industries Ltd, Kolte Patil Developers Ltd, Bhartiya International Ltd and Godavari Biorefineries Ltd are among the other gainers in the BSE's 'B' group today, 11 August 2026.Ind-Swift Laboratories Ltd spiked 19.99% to Rs 284.5 at 12:03 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 3.18 lakh shares were traded on the counter so far as against the average daily volumes of 27509 shares in the past one month. Shekhawati Industries Ltd soared 19.94% to Rs 16.24. The stock was the second biggest gainer in 'B' group. On the BSE, 23433 shares were traded on the counter so far as against the average daily volumes of 8536 shares in the past one month. Kolte Patil Developers Ltd surged 17.53% to Rs 545.2. The stock was the third biggest gainer in 'B' group. On the BSE, 4.39 lakh shares were traded on the counter so far as against the average daily volumes of 11601 shares in the past one month. Bhartiya International Ltd rose 17.13% to Rs 965. The stock was the fourth biggest gainer in 'B' group. On the BSE, 102 shares were traded on the counter so far as against the average daily volumes of 518 shares in the past one month. Godavari Biorefineries Ltd jumped 14.74% to Rs 275.6. The stock was the fifth biggest gainer in 'B' group. On the BSE, 2.01 lakh shares were traded on the counter so far as against the average daily volumes of 10020 shares in the past one month.

1 month agoCapital Market - Live
Corporate
Corporate
Ind-Swift Laboratories reported Rs 255.61 crore received from a convertible warrant issue

Ind-Swift Laboratories Limited informed the BSE Limited and National Stock Exchange of India that there was no deviation or variation in the use of funds raised through a preferential issue of convertible warrants, according to a statement reviewed by the company's Audit Committee for the quarter ended June 30, 2026. The company received Rs 255.61 crore out of a total issue size of Rs 314.60 crore on August 30, 2024, and noted that Rs 58.99 crore became non-receivable from Saral Incorporated VCC Sub Fund 1 due to the warrants' tenure expiring and the allottee failing to convert them into equity.

1 month agoCapital Market - Live
Corporate
Corporate
IND-SWIFT LABORATORIES shareholders approved Articles of Association amendments via e-voting

IND-SWIFT LABORATORIES LTD. announced that shareholders approved amendments to the company’s Articles of Association through an Extra-Ordinary General Meeting on August 5, 2026, via e-voting, specifically addressing the retirement of directors by rotation and re-appointment eligibility in accordance with Section 152 of the Companies Act, 2013 and applicable regulations.

1 month agoCapital Market - Live
Corporate
Corporate
Ind-Swift Laboratories shareholders approved warrants and director reappointment at Wednesday's EGM

Ind-Swift Laboratories Limited held its 1st Extra Ordinary General Meeting (EGM) for the financial year 2026-27 on Wednesday, August 5th, 2026, via video conferencing, according to a corporate disclosure. The meeting, chaired by Sh. Navrattan Munjal, commenced at 11:30 A.M. IST and concluded at 12:01 P.M. IST, with 52 shareholders participating, and resolutions including the issuance of up to 70,00,000 fully convertible warrants and the re-appointment of Sh. Rajinder Kumar Gupta as an independent director, approved via remote e-voting and e-voting during the EGM.

2 months agoCapital Market - Live
Corporate
Corporate
Ind-Swift Laboratories to review quarterly financial results at a board meeting

Ind-Swift Laboratories Ltd. will hold a board meeting on Monday, August 10, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, as announced to the BSE Limited and National Stock Exchange of India Limited.

2 months agoCapital Market - Live
Corporate
Corporate
Ind-Swift Laboratories proposes warrant issue to fund facility expansion and subsidiary investment

Ind-Swift Laboratories Limited notified the BSE Limited and National Stock Exchange of India Limited of a corrigendum to the notice of its Extra Ordinary General Meeting scheduled for August 5, 2026, regarding a proposed preferential issue of 70,00,000 fully convertible warrants to a promoter group entity. The changes, stemming from observations by the BSE and NSE, detail the intended use of proceeds, including expansion of existing manufacturing facilities at Jawaharpur, Derabassi (PB), and Jammu (J&K), research and development, technology upgrades, and an investment in its subsidiary, ISLL Middle East LLC -FZ, Dubai, with a tentative timeline for utilization ranging from December 2028 to December 2029.

2 months agoCapital Market - Live
Corporate
Corporate
Ind-Swift Laboratories schedules EGM

Ind-Swift Laboratories announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 5 August 2026.

2 months agoCapital Market - Live

Frequently asked questions

  1. The share price of INDSWFTLAB as on 5th October 2026 is ₹385.75. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. The past returns of IND Swift Laboratories Ltd (INDSWFTLAB) share are
    • Past 1 week: -5.28%
    • Past 1 month: 6.86%
    • Past 3 months: 79.77%
    • Past 6 months: 174.06%
    • Past 1 year: 278.53%
    • Past 3 years: 329.21%
    • Past 5 years: 509.18%

  3. Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of IND Swift Laboratories Ltd (INDSWFTLAB) is ₹3436.29 Cr as of 5th October 2026.

  4. The 52-week high of IND Swift Laboratories Ltd (INDSWFTLAB) is ₹424.75 and the 52-week low is ₹87.15.

  5. The P/E (price-to-earnings) ratio of IND Swift Laboratories Ltd (INDSWFTLAB) is 79.67. The P/B (price-to-book) ratio is 2.48.

  6. IND Swift Laboratories Ltd (INDSWFTLAB) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  7. You can directly buy IND Swift Laboratories Ltd (INDSWFTLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.